Neoplasm Clinical Trial
Official title:
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
This is a Phase I study designed to evaluate the safety and maximum tolerated dose (MTD) of SGT-94, a novel, tumor-targeted, systemic gene therapy agent for cancer. In addition, we will look for evidence of RB94 expression within tumor tissue after systemic administration of SGT-94.
RB94, a tumor suppressor gene, is a modified form of the retinoblastoma gene, RB110. RB94
has shown enhanced tumor suppressor and tumor cell killing activity compared to RB110 in all
tumor cell types studied to date, including bladder cancer cell lines. Moreover, RB94 has
shown no toxicity to any normal human cells tested.
SGT-94,the agent being tested, is a systemically administered complex composed of the RB94
gene (plasmid DNA)encapsulated in a liposome that is targeted to tumor cells by means of an
anti-transferrin receptor single chain antibody fragment (TfRscFv)attached to the outside of
the liposome. Pre-clinical in vivo efficacy studies have indicated that SGT-94, when
systemically administered, preferentially targets tumor cells and efficiently transfects
them. This results in cancer cell death via mechanisms that are unique for RB94 and also
increases the tumor's response to conventional radiation and chemotherapy.
This Phase I study is designed to evaluate the safety of SGT-94 and to establish a
practically attainable and/or tolerable dose of this anti-cancer agent for use in further
clinical trials. Additionally, evidence of RB94 expression within tumor tissue after
systemic administration of SGT-94 will be sought, and clinically observable anti-cancer
effects in patients will be documented. Enrollment will be targeted to individuals with "RB
negative" tumors, i.e. tumors in which there is no staining for RB protein by
immunohistochemistry (IHC). Preference will be given to patients with tumors in a location
amenable to biopsy following treatment with SGT-94. This would include the prostate,
bladder, superficial lymph nodes and any mass suitable for fine needle aspiration under CT
or ultrasound guidance, or any lesion reachable by endoscopy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT00199836 -
A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
|
Phase 1 | |
| Completed |
NCT01672944 -
Evaluating Biobanking Educational Tools
|
N/A | |
| Not yet recruiting |
NCT02226289 -
Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment
|
Phase 2 | |
| Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
| Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
| Completed |
NCT02747342 -
A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
|
Phase 1 | |
| Completed |
NCT02536586 -
A Study of LY3023414 in Japanese Participants With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02309164 -
The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN).
|
N/A | |
| Completed |
NCT02394821 -
Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide
|
Phase 3 | |
| Completed |
NCT01457196 -
Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions
|
N/A | |
| Completed |
NCT00143533 -
Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05450562 -
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00001835 -
Oxaliplatin in Cancer Patients With Impaired Kidney Function
|
Phase 1 | |
| Completed |
NCT00001341 -
A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease
|
Phase 1 | |
| Completed |
NCT01425008 -
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05101798 -
The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial
|
Phase 2 | |
| Completed |
NCT01920061 -
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
|
Phase 1 | |
| Terminated |
NCT03251924 -
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02851706 -
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
|